Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Braz. j. infect. dis ; 18(6): 660-663, Nov-Dec/2014. tab
Article in English | LILACS | ID: lil-730411

ABSTRACT

During the past decade, studies on the composition of human microbiota and its relation to the host became one of the most explored subjects of the medical literature. The development of high-throughput molecular technologies allowed a deeper characterization of human microbiota and a better understanding of its relationship with health and disease. Changes in human habits including wide use of antimicrobials can result in dysregulation of host–microbiome homeostasis, with multiple consequences. The purpose of this review is to highlight the most important evidence in the literature of host–microbiome interactions and illustrate how these intriguing relations may lead to new treatment and prevention strategies.


Subject(s)
Humans , Gastrointestinal Tract/microbiology , Host-Pathogen Interactions/physiology , Microbiota/physiology
2.
An. acad. bras. ciênc ; 81(3): 571-587, Sept. 2009.
Article in English | LILACS | ID: lil-523982

ABSTRACT

Several epidemiological changes have occurred in the pattern of nosocomial and community acquired infectious diseases during the past 25 years. Social and demographic changes possibly related to this phenomenon include a rapid population growth, the increase in urban migration and movement across international borders by tourists and immigrants, alterations in the habitats of animals and arthropods that transmit disease, as well as the raise of patients with impaired host defense abilities. Continuous surveillance programs of emergent pathogens and antimicrobial resistance are warranted for detecting in real time new pathogens, as well as to characterize molecular mechanisms of resistance. In order to become more effective, surveillance programs of emergent pathogens should be organized as a multicenter laboratory network connected to the main public and private infection control centers. Microbiological data should be integrated to guide therapy, adapting therapy to local ecology and resistance patterns. This paper presents an overview of data generated by the Division of Infectious Diseases, Federal University of São Paulo, along with its participation in different surveillance programs of nosocomial and community acquired infectious diseases.


Várias alterações epidemiológicas ocorreram no perfil das doenças infecciosas hospitalares e comunitárias nos últimos 25 anos. Mudanças sociais e demográficas possivelmente relacionadas com esse fenômeno incluem o rápido crescimento populacional, o aumento da migração urbana e deslocamento através de fronteiras internacionais por turistas e imigrantes, alterações nos habitats de animais e artrópodes que transmitem doença assim como o aumento no número de pacientes com deficiências nas respostas de defesa. Os programas contínuos de vigilância de patógenos emergentes e resistência antimicrobiana são necessários para a detecção em tempo real de novos patógenos assim como para caracterizar mecanismos moleculares de resistência. Para serem mais efetivos, os programasde vigilância dos patógenos emergentes devem ser organizados em uma rede de laboratórios multicêntricos ligados aos principais centros de controle de infecções, públicos e privados. Os dados microbiológicos devem ser integrados a guias terapêuticos adaptando práticas terapêuticas à ecologia local eaos padrões de resistência. O artigo apresenta uma revisão dos dados gerados pela Disciplina de Infectologia, Universidade Federal de São Paulo, contemplando sua participação nos diferentes programas de vigilância de doenças infecciosas hospitalares e adquiridas na comunidade.


Subject(s)
Humans , Communicable Diseases, Emerging , Community-Acquired Infections , Cross Infection , Drug Resistance, Bacterial , Drug Resistance, Fungal , Drug Resistance, Viral , Brazil , Communicable Diseases, Emerging/microbiology , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/virology , Community-Acquired Infections/microbiology , Community-Acquired Infections/prevention & control , Community-Acquired Infections/virology , Cross Infection/microbiology , Cross Infection/prevention & control , Cross Infection/virology , Drug Resistance, Bacterial/drug effects , Drug Resistance, Bacterial/genetics , Drug Resistance, Fungal/drug effects , Drug Resistance, Fungal/genetics , Drug Resistance, Viral/drug effects , Drug Resistance, Viral/genetics , HIV-1 , Hospitals, University , Population Surveillance
3.
Braz. j. microbiol ; 37(3): 218-220, July-Sept. 2006. tab
Article in English | LILACS | ID: lil-442120

ABSTRACT

The aim of our study was to evaluate the accuracy of the chromogenic media Albicans ID2omicron (bioMérieux, France) for the identification of Candida albicans among 330 yeast strains. All C. albicans (100) and C. dubliniensis (20) strains exhibited blue color when cultured on Albicans ID2omicron. However, the blue color was also exhibited by cultures of C. rugosa (30/30) and C. tropicalis (3/50) isolates.


O objetivo do nosso estudo foi avaliar a eficácia do meio cromogênico Albicans ID2ômicron (bioMérieux, France) na identificação de Candida albicans entre 330 amostras de leveduras. As cepas de C. albicans (100) e C. dubliniensis (20) exibiram coloração azul quando semeadas em Albicans ID2ômicron. Contudo, a coloração azul também foi verificada em culturas de C. rugosa (30/30) e C. tropicalis (3/50).


Subject(s)
Candida albicans , In Vitro Techniques , Yeasts , Culture Media , Sampling Studies
4.
Rev. Inst. Med. Trop. Säo Paulo ; 47(2): 109-111, Mar.-Apr. 2005. tab
Article in English | LILACS | ID: lil-399955

ABSTRACT

Dezenove culturas de C. dubliniensis isoladas no Brasil, previamente identificadas através de métodos genotípicos, foram avaliadas pelo kit comercial ID 32C (bioMerieux). Treze culturas foram identificadas como C. dubliniensis, mas as demais (seis) evidenciaram perfil duvidoso, embora o software do sistema sugerisse 83,6% de chances das mesmas pertencerem à espécie C. dubliniensis. A literatura tem registrado grande variabilidade fenotípica com esta espécie e, por isto, as identificações obtidas com este sistema deverão ser consideradas como presuntivas.


Subject(s)
Humans , Candida/classification , Carbohydrates/metabolism , Mycological Typing Techniques/methods , Candida/isolation & purification , Candida/metabolism , Phenotype
5.
Braz. j. infect. dis ; 6(3): 124-128, Jun. 2002.
Article in English | LILACS | ID: lil-332323

ABSTRACT

Problems with resistance to antifungal drugs have emerged due to an increase in the incidence of systemic fungal infections and widespread use of antifungal agents. Accordingly, efforts have been made to develop adequate fungal susceptibility tests. The ideal test should have high intra and inter-laboratory reproducibility, good correlation with the clinical outcome, and should be easy to perform. While no such test has yet been developed, advances have been made. Over the past decade, many reports of fungal resistance have been published, most of them in AIDS patients. Though the frequency of resistant strains is still low in neutropenic cancer patients, and is mostly limited to Candida glabrata and Candida krusei, resistance to Candida albicans has also been reported.


Subject(s)
Humans , Antifungal Agents/pharmacology , Candida , Candidiasis/microbiology , Neutropenia , Drug Resistance, Fungal , Candida , Candidiasis/epidemiology , Incidence , Microbial Sensitivity Tests
6.
Braz. j. infect. dis ; 6(3): 118-123, Jun. 2002.
Article in English | LILACS | ID: lil-332324

ABSTRACT

The increasing magnitude of antifungal resistance as well as the advent of new antifungal drugs has generated a renewed interest in fungal susceptibility testing. We used a previously described disk diffusion method to evaluate the susceptibility profile of a large collection of recent clinical Candida spp. isolates against fluconazole. A total of 1,784 yeast isolates were tested, including the following species: Candida albicans (1,036), C. tropicalis (279), C. parapsilosis (202), C. glabrata (119), C. guilliermondii (90), C. krusei (32), C. lusitaniae (7), Candida spp. (14) and other yeasts (5). Susceptibility ranking to fluconazole obtained with all yeasts tested was: C. parapsilosis congruent with C. tropicalis congruent with C. guilliermondii > C. glabrata > C. krusei. The majority (94) of all yeast isolates tested were susceptible to fluconazole. Isolates of C. glabrata and C. krusei exhibited the highest rate of DDS/resistance among all isolates tested but they represented only 9 of all yeasts routinely sent to our lab. Careful periodical surveillance is needed in order to identify any changes in the susceptibility patterns of fluconazole with the increased use of this antifungal agent in Brazilian tertiary care hospitals.


Subject(s)
Humans , Antifungal Agents/pharmacology , Candida , Candidiasis/microbiology , Fluconazole , Microbial Sensitivity Tests , Drug Resistance, Fungal , Brazil , Candida , Diffusion
7.
In. Farhat, Calil Kairalla; Carvalho, Eduardo da Silva; Carvalho, Luiza Helena Falleiros Rodrigues; Succi, Regina Célia de Menezes. Infectologia pediátrica. Säo Paulo, Atheneu, 2 ed; 1998. p.512-8, tab.
Monography in Portuguese | LILACS | ID: lil-260921
8.
In. Farhat, Calil Kairalla; Carvalho, Eduardo da Silva; Carvalho, Luiza Helena Falleiros Rodrigues; Succi, Regina Célia de Menezes. Infectologia pediátrica. Säo Paulo, Atheneu, 2 ed; 1998. p.512-8, tab.
Monography in Portuguese | LILACS, SES-SP, SESSP-IIERPROD, SES-SP | ID: biblio-1068773
9.
Braz. j. infect. dis ; 1(4): 204-7, Aug. 1997.
Article in English | LILACS | ID: lil-284609

ABSTRACT

A fatal case of Rhodotorula glutinis fungenia in an 11-year-old boy with acute lymphoblastc leukemia undergoing third reinduction chemotherapy is reported. This is the first case of fungemia by Rhodotorula glutinis reported in Brazil.


Subject(s)
Humans , Male , Child , Amphotericin B/therapeutic use , Flucytosine/therapeutic use , Fungemia/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Rhodotorula/classification , Rhodotorula/isolation & purification , Disease , Fatal Outcome , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL